CA3048324A1 - Tianeptine oxalate salts and polymorphs - Google Patents

Tianeptine oxalate salts and polymorphs Download PDF

Info

Publication number
CA3048324A1
CA3048324A1 CA3048324A CA3048324A CA3048324A1 CA 3048324 A1 CA3048324 A1 CA 3048324A1 CA 3048324 A CA3048324 A CA 3048324A CA 3048324 A CA3048324 A CA 3048324A CA 3048324 A1 CA3048324 A1 CA 3048324A1
Authority
CA
Canada
Prior art keywords
tianeptine
oxalate
crystalline
mono
hemi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3048324A
Other languages
English (en)
French (fr)
Inventor
Stefano Luca Giaffreda
Enrico MODENA
Serena Fabbroni
Michel CHIARUCCI
Mark T. Edgar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tonix Pharma Holdings Ltd
Original Assignee
Tonix Pharma Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tonix Pharma Holdings Ltd filed Critical Tonix Pharma Holdings Ltd
Publication of CA3048324A1 publication Critical patent/CA3048324A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
CA3048324A 2016-12-28 2017-12-28 Tianeptine oxalate salts and polymorphs Pending CA3048324A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662439533P 2016-12-28 2016-12-28
US62/439,533 2016-12-28
PCT/IB2017/001709 WO2018122606A1 (en) 2016-12-28 2017-12-28 Tianeptine oxalate salts and polymorphs

Publications (1)

Publication Number Publication Date
CA3048324A1 true CA3048324A1 (en) 2018-07-05

Family

ID=61283255

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3048324A Pending CA3048324A1 (en) 2016-12-28 2017-12-28 Tianeptine oxalate salts and polymorphs

Country Status (13)

Country Link
US (2) US10449203B2 (enExample)
EP (1) EP3562812A1 (enExample)
JP (2) JP2020503330A (enExample)
CN (1) CN110418785A (enExample)
AU (1) AU2017385958B2 (enExample)
BR (1) BR112019013244A2 (enExample)
CA (1) CA3048324A1 (enExample)
IL (1) IL267708A (enExample)
MX (1) MX2019007891A (enExample)
MY (1) MY199385A (enExample)
NZ (1) NZ754797A (enExample)
WO (1) WO2018122606A1 (enExample)
ZA (1) ZA201904185B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ754797A (en) * 2016-12-28 2022-05-27 Tonix Pharma Holdings Ltd Tianeptine oxalate salts and polymorphs
US20240165126A1 (en) 2021-03-15 2024-05-23 Tonix Pharmaceuticals Holding Corp. Tianeptine oxalate and naloxone combination for the treatment of major depressive disorder
CN117769540A (zh) * 2021-05-11 2024-03-26 亚士德制药公司 4-[5-[(3S)-3-氨基吡咯烷-l-羰基]-2-[2-氟-4-(2-羟基-2-乙基丙基)苯基]苯基]-2-氟-苯甲腈的盐的固体形式

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3758528A (en) * 1970-03-13 1973-09-11 Science Union & Cie Tricyclic compounds
FR2635461B1 (fr) * 1988-08-18 1992-01-17 Adir Utilisation de derives tricycliques pour l'obtention de medicaments destines au traitement du stress
US5405842A (en) 1994-01-28 1995-04-11 Silverman; Bernard A. Treatment of steroid dependent asthmatics
FR2791891A1 (fr) 1999-04-07 2000-10-13 Adir Utilisation de la tianeptine pour l'obtention de medicaments destines au traitement des pathologies de la neurodegenerescence
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US9314469B2 (en) 2008-05-05 2016-04-19 Tonix Pharma Holdings Limited Method for treating neurocognitive dysfunction
US8198268B2 (en) * 2008-10-31 2012-06-12 Janssen Biotech, Inc. Tianeptine sulfate salt forms and methods of making and using the same
NZ754797A (en) * 2016-12-28 2022-05-27 Tonix Pharma Holdings Ltd Tianeptine oxalate salts and polymorphs

Also Published As

Publication number Publication date
US10449203B2 (en) 2019-10-22
AU2017385958B2 (en) 2021-12-02
CN110418785A (zh) 2019-11-05
MY199385A (en) 2023-10-25
US10946027B2 (en) 2021-03-16
WO2018122606A1 (en) 2018-07-05
US20200276208A1 (en) 2020-09-03
JP2023001340A (ja) 2023-01-04
NZ754797A (en) 2022-05-27
EP3562812A1 (en) 2019-11-06
ZA201904185B (en) 2021-10-27
AU2017385958A1 (en) 2019-07-11
IL267708A (en) 2019-08-29
US20180338984A1 (en) 2018-11-29
MX2019007891A (es) 2019-12-16
JP2020503330A (ja) 2020-01-30
BR112019013244A2 (pt) 2019-12-24

Similar Documents

Publication Publication Date Title
US10946027B2 (en) Tianeptine oxalate salts and polymorphs
JP2021527043A (ja) 新規の塩および結晶
US7956048B2 (en) Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof
JP2013518857A (ja) ４−［−２−［［５−メチル−１−（２−ナフタレニル）−１ｈ−ピラゾール−３−イル］オキシ］エチル］モルホリン塩酸塩多形体および溶媒和物
JP5899214B2 (ja) ４−［−２−［［５−メチル−１−（２−ナフタレニル）−１ｈ−ピラゾール−３−イル］オキシ］エチル］モルホリン塩酸塩の固体形態
US20240199544A1 (en) Crystalline forms of n,n-dimethyltryptamine and methods of using the same
RS61773B1 (sr) Kristalni oblici antagonista androgenog receptora, postupak njihove pripreme i upotrebe
TWI727517B (zh) 貝前列素-314d晶體及其製備方法
Yunxia et al. Solubility and dissolution rate of progesterone cocrystals using 4-fluorobenzoic acid and 2-hydroxy-6-naphthoic acid as coformers
Hu et al. Solution growth and thermal treatment of crystals lead to two new forms of 2-((2, 6-dimethylphenyl) amino) benzoic acid
EP3800175A1 (en) Hexadecyl treprostinil crystals and methods for preparation thereof
WO2021242677A1 (en) Trka inhibitor
CN112300076B (zh) 一种雄性激素受体抑制剂的晶型及其制备方法
EP3917931A1 (en) Solid state forms of oclacitinib maleate
Costa et al. Enhancing Norfloxacin’s solubility: Development and characterization of new solid-state forms with p-aminobenzoic acid
Chen et al. Pharmaceutical cocrystals of nomegestrol acetate with superior dissolution
HK40016628A (zh) 噻奈普汀草酸盐和多晶型
CN101068827B (zh) 萨洒皂草配基的多晶型物
CN114644669B (zh) 一种黄体酮共晶体的制备方法及其应用
HK40116055A (en) Novel sulfate salt forms of isochroman-imidazole structured alpha-2a adrenoceptor agonist
WO2025237212A1 (zh) 一种嘧啶衍生物葡甲胺盐及其晶型
HK40117519A (en) Solid forms of fasoracetam
CZ310145B6 (cs) Kokrystaly kanabigerolu s piperazinem nebo tetramethylpyrazinem
CN115650955A (zh) Evobrutinib化合物与糖精的共晶晶型及其制备方法
Zmeškalová et al. Systematic Solid Form Screening of Cannabigerol–Novel Cocrystals

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20221223

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20250630

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251229

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260226